U.S. FDA Approves Phase III Cardiopoietic Stem Cell Trial for Heart Failure Patients Based on a Mayo Discovery
Cardio3 BioSciences, an international Mayo Clinic collaborator, has received FDA approval for a phase III pivotal clinical trial of its stem cell therapy.┬áThe trial will test the Mayo Clinic discovery of cardiopoietic (cardiogenically-instructed) stem cells designed to improve heart health in people suffering from heart failure.┬áThe multisite U.S. trial, called CHART-2, will aim to recruit 240 patients with chronic advanced symptomatic heart failure. Cardio3 BioSciences is a bioscience company in Mont-Saint-Guibert, Belgium.
"Regenerative medicine is poised to transform┬áthe way we treat patients," says Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine. Watch the video below to see how stem cells are being used to treat people with heart failure.
Journalists: Video b-roll of today's news conference, plus┬ásound bites with Dr. Terzic and Christian Homsy, M.D., CEO of Cardio3 BioSciences, are┬áavailable in the downloads. The video pkg. is also available in the downloads in MOV format.